PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases
| dc.rights.license | open | en_US |
| hal.structure.identifier | Institut des Maladies Neurodégénératives [Bordeaux] [IMN] | |
| hal.structure.identifier | Acides Nucléiques : Régulations Naturelle et Artificielle [ARNA] | |
| dc.contributor.author | CUNHA, Anthony
ORCID: 0000-0003-0946-4701 IDREF: 25971206X | |
| hal.structure.identifier | Acides Nucléiques : Régulations Naturelle et Artificielle [ARNA] | |
| dc.contributor.author | GAUBERT, Alexandra
IDREF: 150487983 | |
| hal.structure.identifier | Acides Nucléiques : Régulations Naturelle et Artificielle [ARNA] | |
| dc.contributor.author | LATXAGUE, Laurent
ORCID: 0000-0002-6115-7437 IDREF: 074748114 | |
| hal.structure.identifier | Institut des Maladies Neurodégénératives [Bordeaux] [IMN] | |
| dc.contributor.author | DEHAY, Benjamin | |
| dc.date.accessioned | 2022-10-10T10:39:37Z | |
| dc.date.available | 2022-10-10T10:39:37Z | |
| dc.date.issued | 2021-07-08 | |
| dc.identifier.issn | 1999-4923 | en_US |
| dc.identifier.uri | oai:crossref.org:10.3390/pharmaceutics13071042 | |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/148371 | |
| dc.description.abstractEn | Treatment of neurodegenerative diseases has become one of the most challenging topics of the last decades due to their prevalence and increasing societal cost. The crucial point of the non-invasive therapeutic strategy for neurological disorder treatment relies on the drugs’ passage through the blood-brain barrier (BBB). Indeed, this biological barrier is involved in cerebral vascular homeostasis by its tight junctions, for example. One way to overcome this limit and deliver neuroprotective substances in the brain relies on nanotechnology-based approaches. Poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) are biocompatible, non-toxic, and provide many benefits, including improved drug solubility, protection against enzymatic digestion, increased targeting efficiency, and enhanced cellular internalization. This review will present an overview of the latest findings and advances in the PLGA NP-based approach for neuroprotective drug delivery in the case of neurodegenerative disease treatment (i.e., Alzheimer’s, Parkinson’s, Huntington’s diseases, Amyotrophic Lateral, and Multiple Sclerosis). | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.source | crossref | |
| dc.subject.en | PLGA nanoparticles | |
| dc.subject.en | Neurodegenerative diseases | |
| dc.subject.en | Drug delivery | |
| dc.subject.en | Central nervous system | |
| dc.subject.en | Neuroprotective drugs | |
| dc.title.en | PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.3390/pharmaceutics13071042 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio] | en_US |
| dc.identifier.pubmed | 34371733 | en_US |
| bordeaux.journal | Pharmaceutics | en_US |
| bordeaux.volume | 13 | en_US |
| bordeaux.hal.laboratories | Institut des Maladies Neurodégénératives (IMN) - UMR 5293 | en_US |
| bordeaux.issue | 7 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | CNRS | en_US |
| bordeaux.institution | INSERM | |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.import.source | dissemin | |
| hal.identifier | inserm-03285083 | |
| hal.version | 1 | |
| hal.export | false | |
| workflow.import.source | dissemin | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Pharmaceutics&rft.date=2021-07-08&rft.volume=13&rft.issue=7&rft.eissn=1999-4923&rft.issn=1999-4923&rft.au=CUNHA,%20Anthony&GAUBERT,%20Alexandra&LATXAGUE,%20Laurent&DEHAY,%20Benjamin&rft.genre=article |
